🇺🇸 FDA
Patent

US 10813952

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 10813952 (NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K2039/57, A61K2039/572